CMMB logo

Chemomab Therapeutics (CMMB)

Profile

Full Name

Chemomab Therapeutics Ltd.

Ticker Symbol

CMMB

Exchange

NASDAQ

Country

Israel

IPO

February 12, 2019

Indexes

Not included

Employees

20

Key Details

Price

$1.18(+10.68%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$0.78(+62.14% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Feb 20, 25 Maxim Group
Buy
Nov 15, 24 Oppenheimer
Outperform
May 13, 24 Maxim Group
Buy
May 6, 24 Oppenheimer
Outperform
Mar 8, 24 Oppenheimer
Perform
Oct 6, 23 Roth MKM
Buy
Jun 7, 23 Oppenheimer
Perform
Apr 18, 23 Oppenheimer
Outperform
Mar 10, 22 Oppenheimer
Outperform
Dec 7, 21 Aegis Capital
Buy

Institutional Ownership

  • What is the ticker symbol for Chemomab Therapeutics?
  • Does Chemomab Therapeutics pay dividends?
  • What sector is Chemomab Therapeutics in?
  • What industry is Chemomab Therapeutics in?
  • What country is Chemomab Therapeutics based in?
  • When did Chemomab Therapeutics go public?
  • Is Chemomab Therapeutics in the S&P 500?
  • Is Chemomab Therapeutics in the NASDAQ 100?
  • Is Chemomab Therapeutics in the Dow Jones?
  • When was Chemomab Therapeutics's last earnings report?
  • When does Chemomab Therapeutics report earnings?
  • Should I buy Chemomab Therapeutics stock now?

What is the ticker symbol for Chemomab Therapeutics?

The ticker symbol for Chemomab Therapeutics is NASDAQ:CMMB

Does Chemomab Therapeutics pay dividends?

No, Chemomab Therapeutics does not pay dividends

What sector is Chemomab Therapeutics in?

Chemomab Therapeutics is in the Healthcare sector

What industry is Chemomab Therapeutics in?

Chemomab Therapeutics is in the Biotechnology industry

What country is Chemomab Therapeutics based in?

Chemomab Therapeutics is headquartered in Israel

When did Chemomab Therapeutics go public?

Chemomab Therapeutics's initial public offering (IPO) was on February 12, 2019

Is Chemomab Therapeutics in the S&P 500?

No, Chemomab Therapeutics is not included in the S&P 500 index

Is Chemomab Therapeutics in the NASDAQ 100?

No, Chemomab Therapeutics is not included in the NASDAQ 100 index

Is Chemomab Therapeutics in the Dow Jones?

No, Chemomab Therapeutics is not included in the Dow Jones index

When was Chemomab Therapeutics's last earnings report?

Chemomab Therapeutics's most recent earnings report was on Mar 3, 2025

When does Chemomab Therapeutics report earnings?

The next expected earnings date for Chemomab Therapeutics is May 9, 2025

Should I buy Chemomab Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page